{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:58:56Z","timestamp":1782417536765,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Late onset Pompe disease (LOPD) is a slow, progressive disorder characterized by skeletal and respiratory muscle weakness. Enzyme replacement therapy (ERT) slows down the progression of muscle symptoms. Reliable biomarkers are needed to follow up ERT-treated and asymptomatic LOPD patients in clinical practice. In this study, 32 LOPD patients (22 symptomatic and 10 asymptomatic) underwent muscle MRI using 3-point Dixon and were evaluated at the time of the MRI with several motor function tests and patient-reported outcome measures, and again after one year. Muscle MRI showed a significant increase of 1.7% in the fat content of the thigh muscles in symptomatic LOPD patients. In contrast, there were no noteworthy differences between muscle function tests in the same period of time. We did not observe any significant changes either in muscle MRI or in muscle function tests in asymptomatic patients over the year. We conclude that 3-point Dixon muscle MRI is a useful tool for detecting changes in muscle structure in symptomatic LOPD patients and could become part of the current follow-up protocol in daily clinics.<\/jats:p>","DOI":"10.1038\/s41598-018-29170-7","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T13:49:16Z","timestamp":1531403356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study"],"prefix":"10.1038","volume":"8","author":[{"given":"Sebastian","family":"Figueroa-Bonaparte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Llauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Segovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izaskun","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Montiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alonso-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-3436","authenticated-orcid":false,"given":"Eduard","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Illa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Spanish Pompe group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Barba-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseba","family":"Barcena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Carbonell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosario","family":"Carzorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Creus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Coll-Cant\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fern\u00e1ndez-Torr\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Garc\u00eda-Antelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"L\u00f3pez de Mun\u00e1in","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Antonio","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Morgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Mor\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Mu\u00f1oz-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Parajua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Robledo-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Rojas-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ant\u00f3nio","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Us\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"D\u00edaz-Manera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"29170_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1212\/WNL.0b013e31818da91e","volume":"71","author":"B Bembi","year":"2008","unstructured":"Bembi, B. et al. Diagnosis of glycogenosis type II. Neurology. 71, S4\u201311 (2008).","journal-title":"Neurology."},{"key":"29170_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.c.31322","volume":"160C","author":"A Schuller","year":"2012","unstructured":"Schuller, A., Wenninger, S., Strigl-Pill, N. & Schoser, B. Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet. 160C, 80\u201388 (2012).","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"29170_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg, A. T. et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. 362, 1396\u20131406 (2010).","journal-title":"N Engl J Med."},{"key":"29170_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT van der Ploeg","year":"2012","unstructured":"van der Ploeg, A. T. et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Mol Genet Metab. 107, 456\u2013461 (2012).","journal-title":"Mol Genet Metab."},{"key":"29170_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-49","volume":"8","author":"D Gungor","year":"2013","unstructured":"Gungor, D. et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 8, 49 (2013).","journal-title":"Orphanet J Rare Dis."},{"key":"29170_CR6","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini, C. et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 259, 952\u2013958 (2012).","journal-title":"J Neurol."},{"key":"29170_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymgme.2016.01.013","volume":"117","author":"KM Stepien","year":"2016","unstructured":"Stepien, K. M., Hendriksz, C. J., Roberts, M. & Sharma, R. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5 years. Mol Genet Metab. 117, 413\u2013418 (2016).","journal-title":"Mol Genet Metab."},{"key":"29170_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-73","volume":"7","author":"JM de Vries","year":"2012","unstructured":"de Vries, J. M. et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 7, 73 (2012).","journal-title":"Orphanet J Rare Dis."},{"key":"29170_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser, B. et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 264, 621\u2013630 (2017).","journal-title":"J Neurol."},{"key":"29170_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","volume":"80","author":"N Raben","year":"2003","unstructured":"Raben, N. et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab. 80, 159\u2013169 (2003).","journal-title":"Mol Genet Metab."},{"key":"29170_CR11","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus, E. et al. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study. Neurology. 89, 2365\u201373 (2017).","journal-title":"Neurology."},{"key":"29170_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0102-z","volume":"9","author":"P De Filippi","year":"2014","unstructured":"De Filippi, P. et al. Genotype-phenotype correlation in Pompe disease, a step forward. Orphanet J Rare Dis. 9, 102 (2014).","journal-title":"Orphanet J Rare Dis."},{"key":"29170_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1474-4422(15)00242-2","volume":"15","author":"JM Morrow","year":"2016","unstructured":"Morrow, J. M. et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. Lancet Neurol. 15, 65\u201377 (2016).","journal-title":"Lancet Neurol."},{"key":"29170_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/ana.24599","volume":"79","author":"RJ Willcocks","year":"2016","unstructured":"Willcocks, R. J. et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Ann Neurol. 79, 535\u2013547 (2016).","journal-title":"Ann Neurol."},{"key":"29170_CR15","doi-asserted-by":"publisher","first-page":"e90377","DOI":"10.1371\/journal.pone.0090377","volume":"9","author":"TA Willis","year":"2014","unstructured":"Willis, T. A. et al. Quantitative magnetic resonance imaging in limb-girdle muscular dystrophy 2I: a multinational cross-sectional study. PLoS One. 9, e90377 (2014).","journal-title":"PLoS One."},{"key":"29170_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/ana.24743","volume":"80","author":"N Lokken","year":"2016","unstructured":"Lokken, N., Hedermann, G., Thomsen, C. & Vissing, J. Contractile properties are disrupted in Becker muscular dystrophy, but not in limb girdle type 2I. Ann Neurol. 80, 466\u2013471 (2016).","journal-title":"Ann Neurol."},{"key":"29170_CR17","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-017-8547-3","volume":"264","author":"J Burakiewicz","year":"2017","unstructured":"Burakiewicz, J. et al. Quantifying fat replacement of muscle by quantitative MRI in muscular dystrophy. J Neurol. 264, 2053\u20132067 (2017).","journal-title":"J Neurol."},{"key":"29170_CR18","doi-asserted-by":"publisher","first-page":"e70993","DOI":"10.1371\/journal.pone.0070993","volume":"8","author":"TA Willis","year":"2013","unstructured":"Willis, T. A. et al. Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One. 8, e70993 (2013).","journal-title":"PLoS One."},{"key":"29170_CR19","doi-asserted-by":"publisher","first-page":"e0163493","DOI":"10.1371\/journal.pone.0163493","volume":"11","author":"S Figueroa-Bonaparte","year":"2016","unstructured":"Figueroa-Bonaparte, S. et al. Muscle MRI Findings in Childhood\/Adult Onset Pompe Disease Correlate with Muscle Function. PLoS One. 11, e0163493 (2016).","journal-title":"PLoS One."},{"key":"29170_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.nmd.2011.06.748","volume":"21","author":"RY Carlier","year":"2011","unstructured":"Carlier, R. Y. et al. Whole-body muscle MRI in 20 patients suffering from late onset Pompe disease: Involvement patterns. Neuromuscul Disord. 21, 791\u2013799 (2011).","journal-title":"Neuromuscul Disord."},{"key":"29170_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ymgmr.2015.03.010","volume":"3","author":"KM Gruhn","year":"2015","unstructured":"Gruhn, K. M. et al. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy. Mol Genet Metab Rep. 3, 58\u201364 (2015).","journal-title":"Mol Genet Metab Rep."},{"key":"29170_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1146\/annurev.physiol.010908.163216","volume":"71","author":"GQ Wallace","year":"2009","unstructured":"Wallace, G. Q. & McNally, E. M. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol. 71, 37\u201357 (2009).","journal-title":"Annu Rev Physiol."},{"key":"29170_CR23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S1474-4422(16)30035-7","volume":"15","author":"V Straub","year":"2016","unstructured":"Straub, V. et al. Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 15, 882\u2013890 (2016).","journal-title":"Lancet Neurol."},{"key":"29170_CR24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neurol.2016.08.002","volume":"172","author":"F Fatehi","year":"2016","unstructured":"Fatehi, F., Salort-Campana, E., Le Troter, A., Bendahan, D. & Attarian, S. Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach. Rev Neurol (Paris). 172, 566\u2013571 (2016).","journal-title":"Rev Neurol (Paris)."},{"key":"29170_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0672-6","volume":"16","author":"G Grolez","year":"2016","unstructured":"Grolez, G. et al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol. 16, 155 (2016).","journal-title":"BMC Neurol."},{"key":"29170_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2015.11.012","volume":"26","author":"V Straub","year":"2016","unstructured":"Straub, V. & Bertoli, M. Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies? Neuromuscul Disord. 26, 111\u2013125 (2016).","journal-title":"Neuromuscul Disord."},{"key":"29170_CR27","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.nmd.2013.12.012","volume":"24","author":"RJ Willcocks.","year":"2014","unstructured":"Willcocks., R. J. et al. Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord. 24, 393\u2013401 (2014).","journal-title":"Neuromuscul Disord."},{"key":"29170_CR28","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00415-016-8361-3","volume":"264","author":"G Andersen","year":"2017","unstructured":"Andersen, G. et al. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients. J Neurol. 264, 438\u2013447 (2017).","journal-title":"J Neurol."},{"key":"29170_CR29","first-page":"569","volume":"15","author":"PY Baudin","year":"2012","unstructured":"Baudin, P. Y., Azzabou, N., Carlier, P. G. & Paragios, N. Prior knowledge, random walks and human skeletal muscle segmentation. Med Image Comput Comput Assist Interv. 15, 569\u2013576 (2012).","journal-title":"Med Image Comput Comput Assist Interv."},{"key":"29170_CR30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/mus.24653","volume":"51","author":"A Echaniz-Laguna","year":"2015","unstructured":"Echaniz-Laguna, A. et al. Should patients with asymptomatic pompe disease be treated? A nationwide study in France. Muscle Nerve. 51, 884\u2013889 (2015).","journal-title":"Muscle Nerve."},{"key":"29170_CR31","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"ML Hagemans","year":"2005","unstructured":"Hagemans, M. L. et al. Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology. 64, 2139\u20132141 (2005).","journal-title":"Neurology."},{"key":"29170_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10545-015-9825-9","volume":"38","author":"PG Carlier","year":"2015","unstructured":"Carlier, P. G. et al. Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients. J Inherit Metab Dis. 38, 565\u2013572 (2015).","journal-title":"J Inherit Metab Dis."},{"key":"29170_CR33","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","volume":"119","author":"A van der Ploeg","year":"2016","unstructured":"van der Ploeg, A. et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Mol Genet Metab. 119, 115\u2013123 (2016).","journal-title":"Mol Genet Metab."},{"key":"29170_CR34","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/labinvest.3700484","volume":"86","author":"BL Thurberg","year":"2006","unstructured":"Thurberg, B. L. et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest. 86, 1208\u20131220 (2006).","journal-title":"Lab Invest."},{"key":"29170_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ajmg.c.31317","volume":"160C","author":"N Raben","year":"2012","unstructured":"Raben, N., Wong, A., Ralston, E. & Myerowitz, R. Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet. 160C, 13\u201321 (2012).","journal-title":"Am J Med Genet C Semin Med Genet."},{"key":"29170_CR36","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/cdd.2012.52","volume":"19","author":"AC Nascimbeni","year":"2012","unstructured":"Nascimbeni, A. C., Fanin, M., Masiero, E., Angelini, C. & Sandri, M. The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII). Cell Death Differ. 19, 1698\u20131708 (2012).","journal-title":"Cell Death Differ."},{"key":"29170_CR37","doi-asserted-by":"crossref","unstructured":"Ripolone, M. et al. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathol Appl Neurobiol. (2017).","DOI":"10.1111\/nan.12414"},{"key":"29170_CR38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/mus.24936","volume":"53","author":"A Pichiecchio","year":"2016","unstructured":"Pichiecchio, A. et al. Asymptomatic Pompe disease: Can muscle magnetic resonance imaging facilitate diagnosis? Muscle Nerve. 53, 326\u2013327 (2016).","journal-title":"Muscle Nerve."},{"key":"29170_CR39","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1073\/pnas.0700281104","volume":"104","author":"PC van Zijl","year":"2007","unstructured":"van Zijl, P. C., Jones, C. K., Ren, J., Malloy, C. R. & Sherry, A. D. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc Natl Acad Sci USA 104, 4359\u20134364 (2007).","journal-title":"Proc Natl Acad Sci USA"},{"key":"29170_CR40","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.rcl.2017.04.010","volume":"55","author":"L Filli","year":"2017","unstructured":"Filli, L., Winklhofer, S., Andreisek, G. & Del Grande, F. Imaging of Myopathies. Radiol Clin North Am. 55, 1055\u20131070 (2017).","journal-title":"Radiol Clin North Am."},{"key":"29170_CR41","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/mus.25417","volume":"55","author":"A Pichiecchio","year":"2017","unstructured":"Pichiecchio, A. et al. Muscle MRI of classic infantile pompe patients: Fatty substitution and edema-like changes. Muscle Nerve. 55, 841\u2013848 (2017).","journal-title":"Muscle Nerve."},{"key":"29170_CR42","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1007\/s00247-014-3038-5","volume":"44","author":"N Azzabou","year":"2014","unstructured":"Azzabou, N. & Carlier, P. G. Fat quantification and T2 measurement. Pediatr Radiol. 44, 1620\u20131621 (2014).","journal-title":"Pediatr Radiol."},{"key":"29170_CR43","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.2214\/AJR.14.13755","volume":"205","author":"HK Kim","year":"2015","unstructured":"Kim, H. K. et al. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping-Comparison Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. AJR Am J Roentgenol. 205, W216\u2013223 (2015).","journal-title":"AJR Am J Roentgenol."},{"key":"29170_CR44","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg, A. T. et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 24, 768\u2013e31 (2017).","journal-title":"Eur J Neurol."},{"key":"29170_CR45","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1212\/NXG.0000000000000089","volume":"2","author":"E Harris","year":"2016","unstructured":"Harris, E. et al. The Clinical Outcome Study for dysferlinopathy: An international multicenter study. Neurol Genet. 2, e89 (2016).","journal-title":"Neurol Genet."},{"key":"29170_CR46","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2007.02.013","volume":"17","author":"L Vandervelde","year":"2007","unstructured":"Vandervelde, L., den Bergh, P. Y., Goemans, N. & Thonnard, J. L. ACTIVLIM: a Rasch-built measure of activity limitations in children and adults with neuromuscular disorders. Neuromuscul Disord. 17, 459\u2013469 (2007).","journal-title":"Neuromuscul Disord."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29170-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29170-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T07:37:22Z","timestamp":1671608242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-29170-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["29170"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-29170-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]},"assertion":[{"value":"6 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was supported by Sanofi-Genzyme. The company did not interfere in the design of the protocol or review any data obtained from patients. There are no other conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10898"}}